This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

dextromethorphan/quinidine (Nuedexta®)

Reference No. 1582

Publication date:

Appraisal information

dextromethorphan/quinidine (Nuedexta®) 15 mg/9 mg capsule
dextromethorphan/quinidine (Nuedexta®) 23 mg/9 mg capsule

Company: Jenson Pharmaceutical Services Ltd
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Marketing authorisation withdrawn
Advice No: Not available
Ratification by Welsh Government: 02/12/2013

Current Progress

Ratification by
Welsh Government

AWMSG advice

LICENCE WITHDRAWN. Please refer to the European Medicines Agency website for further information. In the absence of a submission from the holder of the marketing authorisation, dextromethorphan/quinidine (Nuedexta®) cannot be endorsed for use within NHS Wales for the symptomatic treatment of pseudobulbar affect in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.
Statement of Advice (SOA)